ABSTRACT
ABSTRACT This research assessed the prevalence of respiratory complaints and the occupational risk factors among municipal solid waste (MSW) collectors. A comparative study was conducted upon MSW collectors in Western Municipality of Mansoura. Sociodemographic and occupational data were collected. Clinical examination and respiratory function measurements were performed. The prevalence of respiratory complaints during the past 12 months was higher among MSW collectors than the service worker group. Older age, cigarette smoking, and longer duration of employment were independently associated with impaired FEV1 (OR = 0.22, 7.2, 0.09, respectively). Older age group of collectors was independently associated with impaired FVC (OR = 0.34). Longer duration of employment was independently associated with impaired FEV1/ FVC (OR = 0.09). Respiratory complaints were prevalent among MSW collectors due to lack of engineering, medical and legislative measures.
Subject(s)
Occupational Diseases/epidemiology , Occupational Exposure/statistics & numerical data , Refuse Disposal/statistics & numerical data , Respiratory Tract Diseases/epidemiology , Adult , Age Factors , Body Mass Index , Cross-Sectional Studies , Egypt/epidemiology , Humans , Male , Prevalence , Protective Devices/statistics & numerical data , Respiratory Function Tests , Risk Factors , Smoking/epidemiology , Socioeconomic Factors , Time FactorsABSTRACT
OBJECTIVE: To investigate the combined effect of both pioglitazone and methotrexate on disease activity of rheumatoid arthritis in a biphasic study; experimental and clinical. METHODS: EXPERIMENTALLY: 50 rats were divided into 5 equal groups; controls, experimental arthritis, methorexate treated (0.1 mg/Kg daily), pioglitazone-treated (10 mg/kg daily), and methotrexate and pioglitazone treated. Clinically: forty-nine diabetic rheumatoid arthritis patients were included. Patients group consisted of 28 patients and they received pioglitazone 30 mg orally beside their usual treatment. Control group consisted of 21 patients and they continued their usual treatment plus placebo. Disease activity was assessed using DAS28 score. Patients were followed up for 3 months. RESULTS: Pioglitazone produced a significant improvement of serum oxidative stress parameters (P < 0.05), and inflammatory cytokines in the treated arthritic group (P < 0.05). Clinically, the pioglitazone treated group showed significant improvement in DAS28 (P = 0.001) and C-reactive protein (P < 0.0001) compared to placebo group. CONCLUSION: The concomitant use of the PPAR γ agonist pioglitazone and methotrexate appears to be promising therapeutic strategy for rheumatoid arthritis patients.
